公开(公告)号：US20240228477A1

公开(公告)日：2024-07-11

申请号：US17909916

申请日：2021-03-12

Applicant: CENTRE REGIONAL DE LUITTE CONTRE LE CANCER FRANCOIS BACLESSE ,  UNIVERSITE DE CAEN NORMANDIE ,  INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE

Inventor： Anne-Sophie VOISIN-CHIRET ,  Charline KIEFFER ,  Nicolas GUEDENEY ,  Camille DENIS ,  Martina DE PASCALE ,  Laurent POULAIN ,  Louis, Bastien WEISWALD ,  Hippolyte PAYSANT

IPC: C07D417/14 ,  A61K47/54 ,  C07D401/14

CPC classification number: C07D417/14 ,  A61K47/545 ,  C07D401/14

Abstract: The present disclosure relates to compounds, compositions and methods for treating cancers and disorders of cell proliferation and more particularly, methods of making and using compounds that modulate at least one of the proteins chosen from Bcl-2, Mcl-1, Bcl-xL, Bcl-w, Bfl-1 and Bcl-B, in particular Bcl-2 protein, or Bcl-xL and/or Mcl-1 proteins. The compounds may be contained in pharmaceutical compositions and used as therapeutic agents.

公开(公告)号：US20190144476A1

公开(公告)日：2019-05-16

申请号：US16097914

申请日：2017-04-27

Applicant: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM) ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ DE MONTPELLIER

Inventor： Tangui MAURICE ,  Jean-Noël VOLLE ,  David VIRIEUX ,  Jean-Luc PIRAT ,  Coralie LABORDE

IPC: C07F9/6584 ,  A61P25/28

Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R′ is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.

公开(公告)号：US20170056397A1

公开(公告)日：2017-03-02

申请号：US15345570

申请日：2016-11-08

Applicant: INSERM (Institut National de la Sante de la Recherche Medicale)

Inventor： Gilles Desmadryl ,  Christian Chabbert

IPC: A61K31/496

CPC classification number: A61K31/496 ,  A61K9/0046

Abstract: The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

Abstract translation: 本发明涉及组胺H 4受体拮抗剂或组胺H4受体基因表达抑制剂，用于治疗和/或预防前庭疾病。

公开(公告)号：US20160228324A1

公开(公告)日：2016-08-11

申请号：US15023710

申请日：2014-09-23

Applicant: KONINKLIJKE PHILIPS N.V. ,  INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM)

Inventor： Philippe Francois Thierry GARTEISER ,  Leon Christiaan TERBEEK ,  Ralph Roman SINKUS ,  Sabrina Nicole Dolorès DOBLAS ,  Simon Auguste LAMBERT ,  Valérie PARADIS

IPC: A61H23/02 ,  A61B5/055

CPC classification number: A61H23/0218 ,  A61B5/055 ,  A61H23/02 ,  A61H23/04 ,  A61H2201/165 ,  A61H2201/5033 ,  A61H2230/00

Abstract: The invention provides for a medical apparatus (100, 200, 300) for treating cells of a subject comprising at least one transducer (102, 224) with a vibrating surface (116). The transducer further comprises an applicator (118, 600) for attaching the vibrating surface to an outer surface of the subject (108, 218). The transducer is operable to vibrate at a frequency between 10 Hz and 1000 Hz. The medical apparatus further comprises a controller (104, 222, 230) for controlling the vibration of the transducer. The controller is operable for causing the transducer to vibrate for greater than a predetermined period of time for treating the cells. The predetermined period of time is greater than one hour.

Abstract translation: 本发明提供一种用于用包含至少一个具有振动表面（116）的换能器（102,224）处理受试者细胞的医疗装置（100,200,300）。 换能器还包括用于将振动表面附接到对象（108,218）的外表面的施加器（118,600）。 换能器可操作以在10Hz和1000Hz之间的频率振动。 医疗装置还包括用于控制换能器的振动的控制器（104,22,230）。 控制器可操作以使换能器振动大于预定时间段以处理细胞。 预定时间段大于1小时。

公开(公告)号：US20210292785A1

公开(公告)日：2021-09-23

申请号：US17331097

申请日：2021-05-26

Applicant: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM)

Inventor： Marisol CORRAL-DEBRINSKI ,  Jose-Alain Sahel ,  Valerie Kaltimbacher ,  Crystel Bonnet

IPC: C12N15/85 ,  A61K48/00 ,  C12N9/02 ,  C07K14/47 ,  C12N9/10

Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3′UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3′UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.

公开(公告)号：US20190204402A1

公开(公告)日：2019-07-04

申请号：US16331732

申请日：2017-09-13

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PARIS DIDEROT - PARIS 7 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Benjamin LEPORQ ,  Jean-Luc DAIRE ,  Bernard VAN BEERS

IPC: G01R33/563 ,  A61B5/055 ,  G01R33/56 ,  A61B5/026 ,  A61B5/0275 ,  A61B5/00

CPC classification number: G01R33/56366 ,  A61B5/0263 ,  A61B5/0275 ,  A61B5/055 ,  A61B5/113 ,  A61B5/4244 ,  A61B5/7207 ,  A61B5/7289 ,  A61B2576/02 ,  G01R33/5601 ,  G01R33/5635 ,  G06T7/0016 ,  G06T2207/30056 ,  G06T2207/30104 ,  G16H30/40

Abstract: The invention relates to liver diseases. Liver diseases notably encompass chronic liver disease and liver cancer (a liver primitive cancer or metastasis). There is therefore a need to be able to extract biomarkers for subjects to suffer from this disease. As a consequence, the inventors worked on a method for post-processing images of a region of interest to obtain at least one perfusion parameter and at least one transport parameter. Such method enables to obtain a method which can be implemented on computer and provides access to relevant parameters for liver diseases in an easier and more accurate way. This method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.

公开(公告)号：US10195195B2

公开(公告)日：2019-02-05

申请号：US15345570

申请日：2016-11-08

Applicant: INSERM (Institut National de la Sante de la Recherche Medicale)

Inventor： Gilles Desmadryl ,  Christian Chabbert

IPC: A61K31/496 ,  A61K9/00

Abstract: The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

公开(公告)号：US20220331333A1

公开(公告)日：2022-10-20

申请号：US17719776

申请日：2022-04-13

Applicant: UNIVERSITE DE STRASBOURG ,  INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Inventor： Yann HERAULT ,  Sandra MARTIN LORENZO

IPC: A61K31/551

Abstract: The present invention relates to the prevention and/or treatment of a neurodevelopmental disorder or a neuropsychiatric disorder comprising administering a therapeutically effective amount of fasudil or a derivative thereof or a pharmaceutical composition comprising fasudil or a derivative thereof, in a subject in need thereof.

公开(公告)号：US20240165198A1

公开(公告)日：2024-05-23

申请号：US18461035

申请日：2023-09-05

Applicant: Gensight Biologics SA ,  Institut National De La Sante De La Recherche Medicale ,  Centre National de la Recherche Scientifique ,  Sorbonne Universite

Inventor： Didier PRUNEAU ,  Anne DOUAR ,  Deniz DALKARA ,  Jens DUEBEL ,  Romain CAPLETTE ,  Gregory GAUVAIN ,  Melissa DESROSIERS ,  Jose SAHEL ,  Serge PICAUD

IPC: A61K38/17 ,  A61K9/00 ,  A61K35/761 ,  A61K36/06 ,  A61K38/16 ,  A61K48/00 ,  A61P27/02 ,  C07K14/405 ,  C12N15/62 ,  C12N15/864

CPC classification number: A61K38/1709 ,  A61K9/0019 ,  A61K9/0048 ,  A61K35/761 ,  A61K36/06 ,  A61K38/16 ,  A61K38/168 ,  A61K38/1767 ,  A61K48/005 ,  A61P27/02 ,  C07K14/405 ,  C12N15/62 ,  C12N15/625 ,  C12N15/8645 ,  A61K48/00 ,  C07K2319/60 ,  C12N2750/14143

Abstract: Disclosed are, among other methods, methods for reactivating retinal ganglion cells in mammals by administering an effective amount of channelrhodopsins (such as ChrimsonR), or an effective amount of such channelrhodopsins (such as ChrimsonR) fused to a fluorescent protein. In the form of protein or nucleic acids, and compositions thereof. The methods may include a light stimuli level inducing RGCs response that is below radiation safety limit. The methods may include delivery by an adenoassociated virus vector. The methods may include use of a CAG promoter. The methods may result in a long term expression of an effective amount of the channelrhodopsins (such as ChrimsonR protein).

公开(公告)号：US20200008945A1

公开(公告)日：2020-01-09

申请号：US16486594

申请日：2018-02-14

Applicant: Institut National De La Sante De La Recherche Medicale (INSERM) ,  Centre Hospitalier Regional Universitaire De Lille ,  Universite De Lille

Inventor： Joel Ferri

IPC: A61F2/30

Abstract: A temporo-mandibular prosthesis including a glenoid part and a condylar part intended to be articulated relative to the glenoid part. The glenoid part including a glenoid support made in a metallic material; and a glenoid insert made in a non-metal lie material, and defining a scat for a head of said condylar part to define said articulation, wherein the glenoid support defines a housing having an opening through which said glenoid insert is insertable into said housing, said opening opening on an external side (E) of said glenoid support, the glenoid support comprising a tab configurable in a passive position and in an active position in which said tab allows and forbids, respectively, the insertion and the extraction, respectively, of said glenoid insert into and out of said housing, respectively.